Early onset of efficacy with erenumab in patients with episodic and chronic migraine

BACKGROUND: Subcutaneous erenumab reduced monthly migraine days and increased the likelihood of achieving a ≥ 50% reduction at all monthly assessment points tested in 2 pivotal trials in episodic migraine (EM) and chronic migraine (CM). Early efficacy of migraine preventive medications is an importa...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwedt, Todd, Reuter, Uwe, Tepper, Stewart, Ashina, Messoud, Kudrow, David, Broessner, Gregor, Boudreau, Guy P., McAllister, Peter, Vu, Thuy, Zhang, Feng, Cheng, Sunfa, Picard, Hernan, Wen, Shihua, Kahn, Joseph, Klatt, Jan, Mikol, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6755616/
https://www.ncbi.nlm.nih.gov/pubmed/30276500
http://dx.doi.org/10.1186/s10194-018-0923-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6755616/
https://www.ncbi.nlm.nih.gov/pubmed/30276500
http://dx.doi.org/10.1186/s10194-018-0923-6

Ejemplares similares